drugset / Trial / NCT05617040
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multi-centre, Phase 1/2, open-label clinical trial of the VTP-850 prime-boost immunotherapeutic in men with biochemical recurrence after definitive local therapy for prostate cancer.
Timeline
- Start
- 2023-01-30
- Primary completion
- 2025-02-05
- Completion
- 2025-02-05
Outcome
Outcome not reported
Stopped: “The trial was discontinued following completion of the Phase 1 portion. This discontinuation was not based on safety concerns.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ChAdOx1-PCAQ | Unknown | 5e+09 unknown | Intramuscular |
| Subject | ChAdOx1-PCAQ | Unknown | 2.5e+10 unknown | Intramuscular |
| Subject | MVA-PCAQ | Unknown | 2e+07 unknown | Intramuscular |
| Subject | MVA-PCAQ | Unknown | 5e+07 unknown | Intramuscular |
| Subject | MVA-PCAQ | Unknown | 2e+08 unknown | Intramuscular |